Aim:In this systematic review,guidelines on non-alcoholic fatty liver disease(NAFLD)were evaluated,aiming at a guideline synthesis focusing on diagnosis and staging.Methods:A systematic literature search was conducted...Aim:In this systematic review,guidelines on non-alcoholic fatty liver disease(NAFLD)were evaluated,aiming at a guideline synthesis focusing on diagnosis and staging.Methods:A systematic literature search was conducted on any relevant database or institutional website to find guidelines on NAFLD assessment intended for clinical use on humans,in English,published from January 2010 to August 2020.Included guidelines were appraised using the AGREE Ⅱ Instrument;those with higher scores and intended for use in adult patients were included in a comparative analysis.Results:Fourteen guidelines were included in the systematic review,eight of which reached an AGREE Ⅱ score sufficiently high to be recommended for clinical use,of which one developed for pediatric patients only.British and North American guidelines received the highest scores.Most guidelines recommend a screening or case-finding approach in patients with metabolic risk factors who are at increased risk of steatohepatitis or fibrosis.Ultrasound is mostly recommended to confirm steatosis,while the presence of metabolic syndrome,liver function tests,fibrosis scores,and elastographic techniques may help in selecting high-risk patients to be referred to the hepatologist,who may consider liver biopsy,although referral criteria for liver biopsy are not clearly defined.Most guidelines identify the development of noninvasive tests to replace liver biopsy as a research priority.Conclusion:Several high-quality guidelines exist for NAFLD assessment,with no complete agreement on whether to screen high-risk patients and on the tests and biomarkers suggested to stratify patients and select those to be referred to liver biopsy.展开更多
文摘Aim:In this systematic review,guidelines on non-alcoholic fatty liver disease(NAFLD)were evaluated,aiming at a guideline synthesis focusing on diagnosis and staging.Methods:A systematic literature search was conducted on any relevant database or institutional website to find guidelines on NAFLD assessment intended for clinical use on humans,in English,published from January 2010 to August 2020.Included guidelines were appraised using the AGREE Ⅱ Instrument;those with higher scores and intended for use in adult patients were included in a comparative analysis.Results:Fourteen guidelines were included in the systematic review,eight of which reached an AGREE Ⅱ score sufficiently high to be recommended for clinical use,of which one developed for pediatric patients only.British and North American guidelines received the highest scores.Most guidelines recommend a screening or case-finding approach in patients with metabolic risk factors who are at increased risk of steatohepatitis or fibrosis.Ultrasound is mostly recommended to confirm steatosis,while the presence of metabolic syndrome,liver function tests,fibrosis scores,and elastographic techniques may help in selecting high-risk patients to be referred to the hepatologist,who may consider liver biopsy,although referral criteria for liver biopsy are not clearly defined.Most guidelines identify the development of noninvasive tests to replace liver biopsy as a research priority.Conclusion:Several high-quality guidelines exist for NAFLD assessment,with no complete agreement on whether to screen high-risk patients and on the tests and biomarkers suggested to stratify patients and select those to be referred to liver biopsy.
